Cancer Immunotherapy

· Progress in Molecular Biology and Translational Science 209. kniha · Elsevier
E‑kniha
300
Počet strán
Vhodné

Táto e‑kniha

Cancer Immunotherapy, Volume 209 covers the progress that has been made in cancer immunotherapy. This volume surveys exciting developments in the field while also highlighting its promise and problems. Chapters in this release include The Promise, Progress, and Challenges of In Situ Immunization Agents in Cancer Immunotherapy, Breakthroughs in Synthetic Controlling Strategies for Precision in CAR-T Therapy, Non-coding RNAs in cancer immunotherapy: a solution to overcome immune resistance?, Rational Design of adjuvants boosts cancer vaccines, Emerging Drug delivery systems to alter Tumor immunosuppressive microenvironment: overcoming the challenges in immunotherapy for Glioblastoma.Other chapters cover Magnetic Nanoparticles: An Emerging Nanomedicine for Cancer Immunotherapy and Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment. - Discusses immune surveillance of tumors and how it is compromised - Presents new approaches to the development and delivery of cancer vaccines and cytotoxic T-cells to the tumor site - Demonstrates how new molecular biological approaches may augment the efficacy of CAR-T cells and dampen the effects of non-coding RNAs
Cancer Immunotherapy, Volume 209 covers the progress that has been made in cancer immunotherapy. This volume surveys exciting developments in the field while also highlighting its promise and problems. Chapters in this release include The Promise, Progress, and Challenges of In Situ Immunization ...

Zistite viac

O autorovi

David B. Teplow, Ph.D., is a Professor of Neurology, Emeritus, at UCLA and an internationally recognized leader in efforts to understand and treat Alzheimer's disease. Dr. Teplow's group has used a multi-disciplinary approach to determine how neurotoxic peptides, such as the amyloid β-protein (Alzheimer's disease) and α-synuclein (Parkinson’s disease), form neurotoxic structures that kill neurons and to develop the means to block these processes. Dr. Teplow received undergraduate training at UC Berkeley; a Ph.D. from the University of Washington; and was a postdoctoral scholar at Caltech. Before coming to UCLA, Dr. Teplow was a faculty member in the Department of Neurology, Harvard Medical School. Dr. Teplow has published >250 peer-reviewed articles, books and book chapters, and commentaries, in addition to serving on numerous national and international scientific advisory boards. Dr. Teplow was a founding editor of the Journal of Molecular Neuroscience and Current Chemical Biology, He is Editor-in-Chief of the Elsevier serial Progress in Molecular Biology and Translational Science and is Associate Editor-in-Chief of the American Journal of Neurodegenerative Disease.

David B. Teplow, Ph.D., is a Professor of Neurology, Emeritus, at UCLA and an internationally recognized leader in efforts to understand and treat Alzheimer's disease. Dr. Teplow's group has used a multi-disciplinary approach to determine how neurotoxic peptides, such as the amyloid β-protein (Al...

Ohodnoťte túto elektronickú knihu

Povedzte nám svoj názor.

Informácie o dostupnosti

Smartfóny a tablety
Nainštalujte si aplikáciu Knihy Google Play pre Android a iPad/iPhone. Automaticky sa synchronizuje s vaším účtom a umožňuje čítať online aj offline, nech už ste kdekoľvek.
Laptopy a počítače
Audioknihy zakúpené v službe Google Play môžete počúvať prostredníctvom webového prehliadača v počítači.
Čítačky elektronických kníh a ďalšie zariadenia
Ak chcete tento obsah čítať v zariadeniach využívajúcich elektronický atrament, ako sú čítačky e‑kníh Kobo, musíte stiahnuť príslušný súbor a preniesť ho do svojho zariadenia. Pri prenose súborov do podporovaných čítačiek e‑kníh postupujte podľa podrobných pokynov v centre pomoci.

Pokračovanie série

Viac od autora David B. Teplow

Podobné e‑knihy